AMGN vs JNJ
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | AMGN | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $439.33 | $270.24 | |
| Market cap as of 2026-08-24 | $237.5B | $651.3B | |
| P/E as of 2026-08-24 | 25.84 | 29.93 | AMGN lower |
| PEG as of 2026-08-24 | 5.48 | 3.39 | JNJ lower |
| Net margin as of 2026-08-24 | +22.9% | +21.5% | AMGN higher |
| Gross margin as of 2026-08-24 | +74.3% | +68.0% | AMGN higher |
| Operating margin as of 2026-08-24 | +30.3% | +25.7% | AMGN higher |
| ROE as of 2026-08-24 | +89.3% | +25.7% | AMGN higher |
| ROA as of 2026-08-24 | +9.5% | +10.6% | JNJ higher |
| Debt / equity as of 2026-08-24 | 4.90 | 0.58 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-24 | +9.1% | +8.1% | AMGN higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +6.2% | AMGN higher |
| Dividend yield as of 2026-08-24 | +3.2% | +3.1% | AMGN higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.41 | 0.20 | |
| 1-year return as of 2026-08-21 close | +48.5% | +51.0% | JNJ higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.